In-Vitro Studies Show MRT Anti-Cancer (Human Breast Cancer) Properties

Share Article

Foundation for Jacobson Resonance (FJR) -- Experimental in-vitro studies at the College of Veterinary Medicine, Mississippi State University, have revealed anti-cancer properties of MRT, with select field-schedules, in human mammary carcinoma cell populations.

that can function as templates for the design of new chemotherapeutic agents, and MRT may potentially serve as a viable adjunctive modality to conventional chemotherapeutic agents. And. finally, MRT instrumentation can be applied as a research tool for further scientific discovery as we seek to palliate human suffering.

Foundation for Jacobson Resonance (FJR) -- Experimental in-vitro studies at the College of Veterinary Medicine, Mississippi State University, have revealed anti-cancer properties of MRT, with select field-schedules, in human mammary carcinoma cell populations.

Ten million times weaker than the earth’s steady magnetic field, millions of times weaker than those magnetic fields emitted by power lines, cellular telephones and computers, these fields are apparently physiologic. Now, we have evidence that they do play a vital role in the structure and function of the state of well being in humans. Three energy field schedules (MRT signals) utilizing the Jacobson Resonator, consistently suppressed the proliferation rate/viability of neoplastic (cancer) cells in-vitro.

Subsequent studies led by Principal Investigator Dr. Cody Coyne at Mississippi State University, have detected a range of biological proteins -- produced by breast cancer cell types -- have had their profiles altered following exposure to the same schedules used in the gene studies, referenced above.

Dr. Coyne states: “Investigations have identified membrane associated complexes that are expressed at elevated or decreased levels in MCF-7 populations following exposure to specific multi-frequency pico-Tesla electromagnetic energy field schedules. Investigations have also detected several mRNA sequences that are expressed in populations of MCF-7 human mammary carcinoma cells following exposure to the same schedules that consistently suppressed the proliferation rate/viability of MCF-7 cell populations.” It is our intent to publish these experimental findings in the near future.

Dr. Jacobson offers: “We look upon these findings as critically important. Indeed, we have identified genes and proteins that are probably involved in suppressing growth and viability of human breast cancer cells that can be regulated non-invasively. Furthermore, the genes and proteins identified may serve as “targets” that can function as templates for the design of new chemotherapeutic agents, and MRT may potentially serve as a viable adjunctive modality to conventional chemotherapeutic agents. And. finally, MRT instrumentation can be applied as a research tool for further scientific discovery as we seek to palliate human suffering.”

For further information please contact Harvey Grossman, Founder & President of the Foundation for Jacobson Resonance at 1.877.439.0514 in North America, and at 561.208.1775 from outside North America. For charitable contributions only, call 561.208.1775.

On February 17, 2004 Section 513(g) of the Federal Food, Drug and Cosmetic Act (Act), Center for Devices and Radiological Health (CDR1-1)indicated it does not intend to enforce pre-market requirements on the Jacobson Resonator. This enforcement discretion applies to this type of device only when it is labeled “solely to enhance feelings of relaxation.”

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Harvey Grossman
Foundation For Jacobson Resonance
561-208-1775
Email >